ABL1 and glioblastoma: Dasatinib, an ATP-competitive inhibitor of PDGFR, c-KIT, BCR-ABL, and SRC, has been evaluated as a monotherapy in patients with GBM relapse for a phase II study (NCT00423735) and resulted ineffective in recurrent GBM.